Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

• Published in: Alzheimer's & dementia Vol. 20; no. 2; pp. 1214 - 1224
• Main Authors: Rissman, Robert A., Langford, Oliver, Raman, Rema, Donohue, Michael C., Abdel‐Latif, Sara, Meyer, Matthew R., Wente‐Roth, Traci, Kirmess, Kristopher M., Ngolab, Jennifer, Winston, Charisse N., Jimenez‐Maggiora, Gustavo, Rafii, Michael S., Sachdev, Pallavi, West, Tim, Yarasheski, Kevin E., Braunstein, Joel B., Irizarry, Michael, Johnson, Keith A., Aisen, Paul S., Sperling, Reisa A.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2024; John Wiley and Sons Inc
• Subjects: Algorithms; Alzheimer Disease - diagnosis; Alzheimer's disease; Amyloid; Amyloid beta-Peptides; Apolipoproteins; Biological markers; Biomarkers; blood‐based biomarkers; Clinical research; Clinical trials; Cognitive ability; Concentration; Dementia; Hispanic Americans; Humans; Individual differences; Mass spectrometry; Medical screening; Pathology; Peptide Fragments; Plasma; Positron emission tomography; Prediction models; Public use; Ratios; Scientific imaging; Spectrometry; Statistical analysis; tau; tau Proteins; Tomography; mass spectrometry; tau; blood-based biomarkers; plasma

INTRODUCTION Incorporating blood‐based Alzheimer's disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency. METHODS Plasma Aβ, phosphorylated tau (p‐tau)181, and p‐tau217 concentration levels from AHEAD 3–45 study participants were measure...